Kaempferol-7-O-rhamnoside

Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure^[1][2][3]. IC50 & Target:α-glucosidase activity^[1] In Vitro:Kaempferol-7-O-rhamnoside (24 h) blocks PD-1/PD-L1 interaction in a dose-dependent manner via activating NFAT transcriptional activity in the co-culture system of PD-1 Jurkat cells and PD-L1/aAPC CHO-K1 cells^[1].
Kaempferol-7-O-rhamnoside (100-500 μM) exerts no significant cytotoxicity on H9c2 cardiomyocytes, and effectively protects H9c2 cardiomyocytes against H2O2-induced damage, as evidenced by the improvement of cell viability^[2].
Kaempferol-7-O-rhamnoside (100-500 μM) significantly upregulates the mRNA expression level of AMPKα1 in H9c2 cardiomyocytes, with a strong positive correlation between its concentration and AMPKα1 expression^[2].
Kaempferol-7-O-rhamnoside (25-100 μM, 24 h) inhibits AST and AKP activities in APAP-induced L02 cells^[3].
Kaempferol-7-O-rhamnoside (100 μM, 24 h) significantly reduces the increase of ROS production in APAP-induced L02 cells^[3].
Kaempferol-7-O-rhamnoside (25-100 μmol/L, 24 h) significantly up-regulates the mRNA expression of FXR and down-regulates the mRNA expression of Cyp7a1 in APAP-induced L02 cells^[3].